Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperbaric bupivacaine + sufentanil is a combination used for spinal (intrathecal) anesthesia, particularly in obstetric and surgical settings such as cesarean section, hip fracture repair, and urological procedures. Hyperbaric bupivacaine is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve fibers, inhibiting nerve impulse transmission and producing sensory and motor block. Sufentanil is a potent lipophilic opioid agonist at the mu-opioid receptor; when added to intrathecal local anesthetics, it enhances analgesia by activating opioid receptors in the dorsal horn of the spinal cord. The combination provides rapid onset and prolonged duration of anesthesia with improved intraoperative analgesia compared to local anesthetic alone. Common side effects include pruritus (itching), with no significant increase in hypotension or vomiting compared to monotherapy[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperbaric bupivacaine + sufentanil.